11:41 AM EDT, 05/13/2024 (MT Newswires) -- Fractyl Health ( GUTS ) said Monday that six-month follow-up data from its German real-world registry study of Revita in patients with type 2 diabetes showed sustained or improved weight loss and better blood glucose control.

The first 14 participants, with advanced type 2 diabetes, experienced an average weight loss of 8.1% and improved glucose control six months after the Revita procedure, the company said. Fasting blood glucose improved from a median of 153 mg/dL at baseline to 116 mg/dL at six months, while HbA1c level improved from 9.2% to 7.6%, according to Fractyl.

So far, 26 of the 33 participants treated in Germany have agreed to join the Revita Registry, the company said. No serious adverse events related to the procedure or the device have been reported, it added.

Price: 6.23, Change: +0.04, Percent Change: +0.65